WO1998004706A1 - Polypeptides utiles comme agents d'immunotherapie et procedes de preparation de polypeptides - Google Patents

Polypeptides utiles comme agents d'immunotherapie et procedes de preparation de polypeptides Download PDF

Info

Publication number
WO1998004706A1
WO1998004706A1 PCT/GB1996/001816 GB9601816W WO9804706A1 WO 1998004706 A1 WO1998004706 A1 WO 1998004706A1 GB 9601816 W GB9601816 W GB 9601816W WO 9804706 A1 WO9804706 A1 WO 9804706A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
protein
hpv
proteins
composition according
Prior art date
Application number
PCT/GB1996/001816
Other languages
English (en)
Inventor
Nigel Richard Whittle
Jeremy Paddon Carmichael
Stephen Edward Connor
Henry Stephen Grammer Thompson
Mark Jonathan Wilson
Original Assignee
Cantab Pharmaceuticals Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Research Limited filed Critical Cantab Pharmaceuticals Research Limited
Priority to CZ99288A priority Critical patent/CZ28899A3/cs
Priority to PCT/GB1996/001816 priority patent/WO1998004706A1/fr
Priority to HU9904137A priority patent/HUP9904137A3/hu
Priority to NZ333799A priority patent/NZ333799A/xx
Priority to BR9612675A priority patent/BR9612675A/pt
Priority to IL12826996A priority patent/IL128269A0/xx
Publication of WO1998004706A1 publication Critical patent/WO1998004706A1/fr
Priority to NO990398A priority patent/NO990398L/no
Priority to FI990157A priority patent/FI990157A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to HPV polypeptide preparations and their use in prophylactic or therapeutic treatment of chronic HPV infection.
  • Methods of preparing these combinations including protein purification techniques and the engineering of nucleic acid sequences by recobinant DNA techniques in order to enhance and achieve high level expression of a particular protein in heterologous cells, in particular E. coli bacterial cells, are generally applicable in the field of protein production and form a further aspect of the invention.
  • HPV Human papillomaviruses
  • HPV Human papillomaviruses
  • HPV are agents responsible for several benign and malignant lesions which proliferate in the skin and mucosal surfaces of humans. They are a genetically diverse group of DNA viruses which infect epithelial tissue, and can cause a range of different human diseases. Over 60 different types of HPV have been distinguished, based on the extent of cross hybridisation between their genomes, and of those, different subgroups are associated primarily with different types of disease. For example HPVs of types 1, 2. etc are associated with cutaneous warts of the hands and feet. HPVs 5 and 8 are associated with the rare disorder epidermodysplasia verruciformis. Approximately twenty HPV types infect the genital mucosa.
  • the first group include viruses such as HPV-6 and HPV-11 which are associated with the majority of benign condylomas (warts), including genital warts.
  • the second group includes HPVs 16.18, 31, 33 and 45, associated with flat warts of the cervix, and involved in malignant conversions leading to carcinomas of the uterine cervix (zur Hausen. Cancer Res, 49 (1989) pp 4677-4681).
  • Warts epithelial tissue
  • the virus infects the basal non-keratinised cells of the epithelium but cannot complete its replication cycle in these cells. Instead virus gene expression is limited to a set of early proteins which can induce the infected cell to proliferate, giving rise to the characteristic wart. In the upper layers of the wart however, the infected cells begin to undergo terminal differentiation towards their final keratinised state, and this differentiation is sufficient to allow the virus to complete its replication cycle with the production of virus proteins and ultimately new virus particles. These lesions, although proliferative. are at low risk of malignant conversion, and in most cases the warts remain benign.
  • HPV infections are also common in patients with impaired cellular immunity, where persistence of viral disease suggests poor immune surveillance.
  • HPV proteins such as LI. L2 in the preparation of vaccines is known for example from WO 93/02184 (Univ of Queensland & CLS Ltd: I Frazer et al: Papilloma virus vaccine).
  • Other HPV proteins have been deeri ed for use in imunodiagnostics, e.g. in WO 91/18294 (Medscand AB: J Dillner et al : Synthetic peptides of various human papillomaviruses, for diagnostic immunossay); and EP 0375555 (Medgenix: G De Martynoff et al: Peptides, antibodies against them, and methods for detection and dosage of papilloma virus).
  • EP 0 456 197 (1991) (Behringwerke: C Bleul et al) discloses peptides with one or more seroreactive epitopes of defined sequence from HPV18 proteins El, E6, and E7.
  • EP 0 451 550 (1991) (Behringwerke: M Mueller et al) discloses peptides with one or more seroreactive epitopes of defined sequence from HPV16 proteins E4, E6, E7. or LI. The disclosures are for screening test purposes, and also mention vaccine use.
  • WO 93/00436 disclose papi11omavirus proteins and fragments related to L2 protein for prophylaxis and therapy of papi11omavirus tumours, also mentioning preparation of E7 protein.
  • WO 92/16636 discloses genetic sequences of HPV16 and HPV18 E6 and E7 as fused genes inserted in a recombinant vaccinia virus vector, causing in-vivo expression of antigens after administration of the live virus vector.
  • WO 92/05248 (Bristol-Myers Squibb: EK Thomas et al) proposes materials for inhibiting and treating human papi11omavirus infection and cell transformation, mentioning recombinant cells (including virus vectors) containing a gene encoding a peptide substantially corresponding to a region of the E6 and/or E7 gene product or a chimeric peptide compound of one or more regions of HPV proteins.
  • the present invention provides fusion polypeptides and aggregates of polypeptides having papi11omavirus-derived antigens as described more particularly below, and compositions thereof and their use for immunogenic and vaccine purposes in eliciting papi11omavirus-specifie immune responses.
  • polypeptides and polypeptide compositions comprising an antigenie determinant of a papi11omavirus protein, in aggregated form which when in solution or dispersion can pass through a sterilisation filter, or in amorphous aggregated form.
  • the invention also provides fusion polypeptides that combine papilloma-virus-derived antigens, e.g. from each of at least two different papi11omavirus proteins, e.g. comprising (a) at least an antigenie determinant of a papi11omavirus L2 protein, and (b) at least an antigenie determinant selected from El, E2, E4. E5, E6 and E7 papi11omavirus proteins and L2 papi11omavirus proteins of different papi11omavirus type than in (a). Further fusion polypeptides provided hereby comprise antigenie determinants from at least two papi11omavirus proteins selected from El, E2. E4, E5, E6 and E7 papi11omavirus proteins e.g. where the said proteins are from different papi11omavirus types.
  • Particularly preferred polypeptides and compositions hereof comprise antigenie determinants of human papi11omavirus proteins, e.g. of HPV type 6, 11, 16, 18. Antigenie determinants of proteins from other HPV types and proteins of non-human animal papi11omaviruses can also be made and used.
  • the invention provides for example polypeptides comprising antigenie determinants from each of at least two different HPV proteins.
  • An antigenie determinant of a papi11omavirus protein can for example be represented and provided in connection with the invention either by the full sequence of the papi11omavirus protein concerned, or by such sub-sequences as may be desired, e.g. a sequence fragment comprising at least 25*. e.g. at least 50* or 75* of the full sequence of the protein concerned, e.g. a N-terminal or C-terminal sequence fragment. Sequences can be taken from clinical papi11omavirus isolates or published sequences or uteins thereof.
  • HPV proteins of which antigenie determinants can form part of such a fusion polypeptide, can be selected for example from the LI. L2, El. E2. E4, E5, E6 and E7 proteins. Proteins of for example (human) papi11omavirus types HPV 6, 11, 16 and 18. as well as from other human or animal papi11omavirus types can be used. Thus antigenie determinants of at least two papi11omavirus proteins can for example be L2 and another, and/or E7 and another.
  • the polypeptide can comprise at least an antigenie determinant from each of at least two different papi11omavirus proteins, and from the same or from different papi11omavi us types.
  • at least one of the proteins can be selected from LI or L2 and/or at least one of the proteins can be selected from El, E2, E4, E5, E6 and E7.
  • the invention provides a polypeptide comprising an antigenie determinant of HPV L2 protein and an antigenie determinant of HPV E7 protein, suitably comprising for example a substantially full length L2 and/or E7 protein of HPV, or antigenie fragments or muteins thereof.
  • a fusion protein comprising L2 and E7 proteins of HPV. can comprise a sequence fragment of at least 50* of the full sequence of each of L2 protein and E7 protein, e.g. substantially the full sequence of L2 and of E7: optionally further including a sequence of LI protein.
  • the polypeptide may further include antigenie determinants of other HPV proteins or be in admixture or aggregated with other HPV proteins or protein fragments, such as LI or another member or members of the L or E series of papi11omavirus-encoded proteins.
  • the polypeptide can comprise a single protein consisting of a fusion of L2 and E7 or a fusion of L2. E7 and LI. Alternatively the polypeptide can comprise an L2-E7 fusion combined with LI protein for prophylactic or therapeutic application.
  • the polypeptide may comprise a fusion molecule or can be derived from individual polypeptides coupled or aggregated together. Soluble or solubiUsed forms of the polypeptide fall within the scope of the invention.
  • the polypeptide can be coupled by chemical crosslinking, in per se known manner, e.g. by standard techniques involving covalent attachment for example to exposed tyrosine residues or to the epsilon-amino groups of lysine residues or the carboxyl groups of aspartate and glutaate residues.
  • Preferred embodiments are however fusion proteins each resulting from expression in a recombinant host cell of a polynucleotide sequence of which part encodes part of all of the amino acid sequence of a first papi11omavirus protein and another part encodes part or all of the amino acid sequence of a second papi11omavirus protein.
  • the invention provides for example a polypeptide comprising an antigenie determinant from each of at least two different papi11omavirus proteins, in an aggregated form which when in solution or dispersion can pass through a sterilisation filter, e.g. a filter with pore size in the range 0.16-0.22 micron, e.g.0.2 micron.
  • a sterilisation filter e.g. a filter with pore size in the range 0.16-0.22 micron, e.g.0.2 micron.
  • the invention provides for example a polypeptide comprising an antigenie determinant from each of at least two different papi11omavirus proteins, e.g. L2 or LI and at least one other of LI, L2, El, E2, E4, E6 and E7, in a reaggregated form that when in solution or dispersion can pass through a sterilisation filter, e.g. a filter with a pore size in the range 0.16 - 0.22 micron, e.g.0.2 micron.
  • a sterilisation filter e.g. a filter with a pore size in the range 0.16 - 0.22 micron, e.g.0.2 micron.
  • Suitable forms of preparation can result for example by denaturation, or denaturation with reduction, e.g. with subsequent reaggregation of a polypeptide which can be a fusion protein or other papi11omavirus protein, e.g. a single papi11omavirus protein, expressed in the form of inclusion bodies in a recombinant host cell.
  • a polypeptide which can be a fusion protein or other papi11omavirus protein, e.g. a single papi11omavirus protein, expressed in the form of inclusion bodies in a recombinant host cell.
  • Such a form can offer an advantage in that it can be relatively easily purified, e.g. for vaccine use.
  • Aggregated or reaggregated polypeptides as described herein can have for example masses in the range about 100,000. e.g. 160.000 to 10.000,000 dal on.
  • the molecular weight of a di er of L2E7 can be about 130,000.
  • the aggregates can for example have diameters on electron microscopy in the range about 4 to 50 nm, e.g. 10 to 15 nm.
  • polypeptide provided by the invention contains a reaggregated L2E7 fusion polypeptide containing aggregates of about 500.000 dalton. about 10-15 or 15-20 nm in diameter upon electron microscopy, with about 7-10, e.g. about 8 L2E7 fusion polypeptide chains per aggregate. More generally, the product can have about 2 to 200, e.g.5-50 chains per aggregate particle, and the preparations of aggregate can comprise particles with a range of particle sizes within the composition.
  • Suitable reaggregation is obtainable for example as a result of slow or gradual removal of urea and thiol -reducing agent (often e.g. dithiothreitol, or other acceptable thiol -reducing agent such as glutathione) from a denatured and reduced preparation of the fusion polypeptide in urea (e.g. about 8M urea) and thiol -reducing agent e.g. about 10 mM dithiothreitol (preferably lowered to about 0.1 mM or less, e.g. about 0.04 mM or less in the reaggregated product).
  • thiol -reducing agent often e.g. dithiothreitol, or other acceptable thiol -reducing agent such as glutathione
  • thiol -reducing agent e.g. about 10 mM dithiothreitol (preferably lowered to about 0.1 mM or less, e.g.
  • the denatured and reduced preparation of the fusion polypeptide is obtainable for example by solubiusing, in urea and thiol -reducing agent, initially-insoluble inclusion bodies as produced by expression of the polypeptides in a E.coli T7 system.
  • Such aggregated soluble or disperse products are often amorphous, can lack LI protein, and are otherwise distinct from virus-like particles based on papi11omavirus LI protein (and sometimes including other papi11omavirus proteins), as reported to result from expression of HPV genes (including LI) in systems such as e.g. recombinant baculoviruses in insect cells or in yeast cells.
  • the virus-like particles have not been disclosed as having undergone solubiusing denaturation and thiol -reduction followed by reaggregation.
  • the polypeptides mentioned above can suitably be prepared using recombinant DNA techniques.
  • the invention also provides nucleic acids which encode the above mentioned polypeptides, cloning and expression vectors incorporating them and parts of them, and transfected and transduced host cells incorporating such nucleic acids and able to express them as protein.
  • the nucleic acid comprises a fusion gene comprising for example the L2 and E7 genes isolated for example from an isolate of HPV-6 obtained from a clinical specimen of genital wart.
  • the polypeptides described above are prepared by expression of the nucleic acid in a prokaryotic or eukaryotic host using recombinant DNA techniques.
  • a nucleic acid which encodes the desired polypeptide is incorporated into a suitable vector system as a suitable open reading frame with any accessory sequences proper for its expression in a chosen system.
  • the host cell is transformed with the vector.
  • Transformed host cells are then cultured and the desired polypeptide isolated from the culture, either from the supernatant or from the cells, as in examples given below.
  • the above-mentioned vectors as well as transformed host cells form a further aspect of the invention.
  • polypeptides provided by the invention has been examined in yeast and baculovirus expression systems, which have been previously reported to allow expression of HPV-derived genes. It was found that in both cases it was possible to obtain expression of a full- length molecule, but that expression levels were sometimes low. It is presently preferred, for the sake of optimising expression levels, to use a prokaryotic host expression system (particularly a E.coli T7 system), rather than the two tested eukaryotic systems (yeast or baculovirus).
  • Immunogenic polypeptides and vaccine compositions provided hereby are useful in eliciting HPV-specific immune responses e.g. as vaccines for prophylaxis or therapy of papi11omavirus-associated conditions.
  • the immunogens e.g. immuno-therapeutic or prophylactic vaccines for use in the prophylaxis or treatment of HPV-associated diseases can be used to generate immune responses, e.g.
  • Such immune response can be targeted towards T-cells, e.g. CD4+ cells, e.g. by the use of appropriate aduvants.
  • the invention further provides a method for preventing or treating HPV infection or lesions associated therewith, which method comprises administering to a patient an effective amount of a polypeptide as described herein.
  • a polypeptide as described herein include vaccine preparations based on polypeptides as mentioned herein, which according to specificity are intended for use in eliciting immune responses to papi11omavirus. particularly for example of papi11omaviruses of types HPV 6 and 11. and of types HPV 16 and 18. for use in prophylaxis and therapy of human genital warts and of cervical intra-epithelial neoplasia.
  • the invention provides immunogenic compositions of the polypeptides mentioned above, suitable for administration by injection, comprising a carrier such as an immunological adjuvant.
  • a carrier such as an immunological adjuvant.
  • the adjuvant comprises alumimium hydroxide and/or monophosphoryl lipid A as decribed more particularly below.
  • Such immunogenic compositions can comprise an adsorption complex comprising "alum" (i.e. aluminium hydroxide usually Alhydrogel (TM) or Rehydrogel (TM) as conventionally used as vaccine adjuvant) having adsorbed thereon a polypeptide obtainable as mentioned above.
  • alum i.e. aluminium hydroxide usually Alhydrogel (TM) or Rehydrogel (TM) as conventionally used as vaccine adjuvant
  • TM aluminium hydroxide usually Alhydrogel (TM) or Rehydrogel (TM) as conventionally used as vaccine adjuvant
  • the adsorption complex can be a binary complex consisting of the alum and the polypeptide, or there may be further constituents, e.g. MPL as described below, making for example a ternary complex of MPL, alum and polypeptide.
  • polypeptide either soluble or aggregated, may be used as vaccine directly or may be administered as a pharmaceutical composition comprising also a pharmaceutically acceptable vehicle, buffer, adjuvant or other acceptable material.
  • a vaccine or pharmaceutical composition which comprises a polypeptide as described above in combination with a suitable carrier or excipient.
  • the polypeptide can be either a soluble monomer, for example of L2E7, or a polypeptide aggregate.
  • the polypeptide e.g. an L2E7 fusion protein
  • an adjuvant or other accessory substance such as an immunostimulatory molecule
  • useful adjuvants include, but are not limited to; aluminium hydroxide ("alum"), e.g. in the form of Alhydrogel (TM) or Rehydrogel (TM); 3D-MPL (3- deacylated monophosphoryl lipid A) e.g.
  • cytokines such as interleukins, including but not limited to GM-CSF, IL-3, IL-2. IL- 12 and IL-7.
  • cytokines such as interleukins, including but not limited to GM-CSF, IL-3, IL-2.
  • IL- 12 and IL-7 Such adjuvants and/or other accessory substances, can be used separately or in combinations as desired.
  • compositions such as vaccines can e.g. be: emulsified in acceptable mineral or hydrocarbon oil. including but not limited to squalene. or biodegradable mineral oils as described in specifications W091/00106 and W091/00107 (SEPPIC: B Brancq et al: describing injectable multi -phase emulsions and emulsion vectors with continuous oily phase); or encapsulated, e.g. by encapsulation in biodegradable microparticles or liposomes or nonionic surfactant vesicles: for these techniques see respectively e.g.
  • polypeptides may be given for therapeutic or prophylactic purposes.
  • Routes and procedures of administration include, but are not limited to standard intramuscular, subcutaneous, intradermal, intravenous, oral or rectal routes and procedures.
  • the amount of polypeptide administered can be chosen according to the formulation and the condition to be treated. Generally it is expected that doses will be between l-2000 ⁇ g of the protein, preferably 10-300 ⁇ g, e.g. 10-250 ⁇ g. Optimal amounts can readily be determined in subjects. One or more doses of the vaccine may be administered at intervals (see e.g. Example 13). This regime can readily be optimised in subjects.
  • a nucleic acid encoding said polypeptide can be incorporated into a suitable recombinant virus vector and introduced into a host organism, such as a human, in order that expression of the nucleic acid can give rise to the polypeptide in situ.
  • viruses suitable for use as basis of recombinant virus vectors in this way are for example viruses as described in WO 92/05263 (Immunology Ltd: SC Inglis et al) and WO 92/16636 (Immunology Ltd: MEG Boursnell et al).
  • Vaccines containing HPV-related polypeptides as described herein may activate broad HPV-specific immune responses.
  • immune responses can include; specific antibody, including HPV6 and HPV11 neutralising antibodies, cell mediated immunity including HPV6 and HPV11 specific lymphoproliferative responses, delayed type hypersensitivity responses, cytotoxic T cells, and cytokine production.
  • the applicants have arranged a technique which can enhance and achieve high level expression of a particular polypeptide in heterologous cells, in particular E. coli bacterial cells.
  • the invention provides a method for preparing a recombinant polypeptide which method comprises expressing in a bacterial cell a nucleic acid sequence which encodes the desired polypeptide but which has been mutated such that codons or groups of codons which cause premature termination of transcription or translation have been replaced by degenerate codons.
  • recombinant polypeptides are found in insoluble aggregates or 'inclusion bodies' (IBs) within the cell.
  • IBs insoluble aggregates or 'inclusion bodies'
  • the applicants have arranged a improved technique for the recovery of said recombinant polypeptides.
  • a method of recovering a recombinant polypeptide from an inclusion body within a prokaryotic host cell comprising subjecting a suspension comprising said inclusion bodies along with unwanted material e.g. broken-cell debris to cross-flow filtration and recovering recombinant polypeptide from inclusion bodies separated therefrom.
  • This technique has the combined effect of separating inclusion bodies present in a cell homogenate from other cell debris and at the same time washing them, hence providing a useful degree of purification.
  • the separated inclusion bodies are subsequently solubilised in situ and the polypeptide is recovered from the solution.
  • solubiUsing reagents include urea and mixtures of urea and dithiothreitol or other sulphydryl reducing agent, e.g. at about 8M-10M concentration.
  • a particular example of a protein preparation of the invention would comprise a fusion protein comprising L2E7 proteins based on HPV-6.
  • the protein is suitably expressed in E. coli cells, purified to homogeneity and then formulated with an adjuvant, for example alum.
  • the preparation would be of use in treating genital warts and would be formulated so as to be in a form suitable for administration by parenteral injection to the recipient patient.
  • Figure 1 shows a nucleotide sequence for a vector expressing a HPV L2E7 fusion protein according to an embodiment of the invention
  • Figures la and lb show sequences of the vector that precede the start codon and follow the stop codon in the sequence of Figure 1;
  • Figure 2 shows a corresponding a inoacid sequence;
  • Figure 3 illustrates a protein purification procedure for use according to an embodiment of the invention in purifying the L2E7 fusion protein of Figures 1 and 2.
  • HPV genes in particular the LI, L2 and E7 genes from the HPV-6 virus.
  • the gene sequences have been used as described herein to construct gene fusions for expression of HPV-6 proteins to high levels in prokaryotic and eukaryotic systems.
  • plasmid vectors for the expression of the above- described polypeptides such as HPV-6, L2 and E7 as a single fusion protein in E. coli have been constructed.
  • Genes from the HPV-6 virus were amplified by Polymerase Chain Reaction (PCR) from a viral DNA sample prepared from a single clinical isolate of wart tissue infected with HPV-6. The genes isolated were used to construct a gene fusion cassette for the expression of HPV-6 derived protein in a heterologous system.
  • PCR Polymerase Chain Reaction
  • PelB leader a leader sequence at the N terminus of the encoded protein sequence in order to enhance the expression of the protein in E. coli cells (but not to direct the expression to the periplasma).
  • His-Tag a sequence at the C terminus of the encoded protein sequence in order to allow purification of the protein by metal chelation chromatography.
  • HPV-6 L2E7 mutated HPV-6 L2E7 gene fusion was subcloned into a plasmid expression vector driving expression of cloned sequences from a bacteriophage T7 promoter (pET expression system, Novagen).
  • the plasmid construct obtained, designated pGW53. chosen for HPV-6 L2E7 expression, encoded an upstream leader sequence, pelB. the HPV- 6 L2E7 ORF's and a downstream sequence encoding 6 histidine residues (His Tag) "in frame" with the C-terminus of the HPV-6 fusion protein.
  • sequence data in Figures 1 and 2 indicate, without limitation, nucleotide and encoded aminoacid sequence of a preferred example of the L2E7 fusion protein produced by the techniques described herein, including an upstream leader and a downstream tag sequence.
  • the leader sequence as well as the tag sequence (aa 591-601) can be omitted if desired.
  • Figures la and lb show non-coding sequences in the preferred T7 expression vector. which precede the start codon and follow the stop codon in Figure 1.
  • Figure 2 shows the sequence of the preferred fusion protein of L2 and E7.
  • locations 7 to 1812 encode a L2E7 fusion protein and tags.
  • the sequence regions corresponding to L2 and E7 in Figures 1-2 have been found to incorporate a few differences by comparison with published separate aminoacid sequences of L2 and E7.
  • a fusion protein expressed with precise correspondence with the published sequences, and incorporated in compositions as disclosed herein would be highly cross-reactive with the preferred L2E7 fusion protein shown in Figures 1 and 2 and would elicit equivalently similar or highly cross-reactive immune responses.
  • Also functionally similar would be L2E7 fusion proteins derived from the sequences of other clinical isolates of HPV: such further isolates from the clinical environment could possibly have discrepancies of sequence as compared with the sequences given here, but these are expected not to be significant to the performance of the invention. If desired, any discrepancies found in a particular clinical isolate could readily be eliminated e.g. by site-specifie mutagenesis of the corresponding cloning vectors prepared therefrom.
  • the gene construct obtained as described herein was inserted in an expression system optimised for high level expression of heterologous proteins in E. coli cells.
  • This expression system was based on the growth of E. coli cells to a significant density followed by induction of the T7 polymerase within the cells, which leads to the high level transcrption of the gene construct.
  • the protein product which was then expressed and accumulated within inclusion bodies inside the E. coli cells. Following harvest of the cells, the protein was purified away from bacterial proteins, and prepared as a solubiused protein extract.
  • This protein extract comprises a high molecular mass aggregate of protein molecules, which is soluble in an aqueous solution.
  • the purified protein thus obtained can be used to form the basis of a therapeutic antigen product in particular for the treatment of genital warts.
  • Viral DNA of the HPV type in the infected tissue was originally deduced by PCR using a method based on a modification of the method of Snijders et al., 1990, Journal of General Virology. 71: pp 173-191 with standard primers for HPV-6.
  • HPV-6 LI, L2 and E7 genes were amplified by Polymerase Chain Reaction (PCR) from a viral DNA sample prepared from a single clinical isolate (H26) selected as the basis for development of the therapeutic entity on the basis of the ease of isolation of genes. The identity of the clinical isolate is not important and any ordinary clinical isolate of HPV-6 would be practically equivalent even though not identical.
  • Initial PCR was performed using Taq DNA polymerase.
  • Oligonucleotide primers used in the PCR reactions encoded 24 nucleotides of exact homology to the gene sequence of interest as well as additional nucleotides where these encoded restriction enzyme sites or were added to maintain the reading frame between eventual gene fusions or to introduce stop codons in the final expression constructs.
  • An example of the oligonucleotide used is as follows:
  • JPC08 CAGTGTCGACGGTCTTCGGTGCGCAGATGGGACA SEQ ID NO 1
  • Non-coding strand oligonucleotide primer for amplification of HPV 7 E7 gene and Sail site for directional cloning are included in Non-coding strand oligonucleotide primer for amplification of HPV 7 E7 gene and Sail site for directional cloning.
  • the single PCR products from the amplification reactions of the LI. L2 and E7 genes were used as template DNA in sequencing reactions to generate a consensus sequence for each of the three genes.
  • the consensus DNA sequence was assumed to be an accurate reflection of the actual DNA sequences of the genes in the viral DNA extracts because it was a sequence generated from many individual template molecules.
  • HPV-6 L2 gene was amplified by PCR from HPV-6 viral DNA as a single product of approximately 1400 bp.
  • the product was purified from agarose and used as a template for DNA sequence analysis, and a consensus sequence for the amplified L2 gene was generated using oligonucleotde primers.
  • the purified L2 product was directly subcloned into the vector pGEM-T to create plasmid pGW12.
  • L2 gene was generated from the pGW12 template DNA using the same oligonucleotide primers as for the consensus sequence.
  • the DNA sequence of the cloned L2 gene was shown to be identical to that of the consensus.
  • the HPV-6 E7 gene was amplified by PCR from HPV-6 viral DNA as a single product of approximately 300 bp. This was purified from agarose and used as template for DNA sequence analysis, and a consensus sequence for the amplified gene was generated using oligonucleotide primers.
  • the purified E7 PCR product was directly subcloned into the vector pGEM-T to create plasmid pGW04.
  • E7 gene was generated from the pGW04 template using the same oligonucleotide primers as for the consensus sequence. The sequence of the cloned E7 gene was shown to be identical to that of the consensus.
  • HPV-6 LI gene was amplified by PCR from HPV-6 viral DNA as a single product of approximately 1500 bp. This was purified from agarose and used as a template for DNA sequence analysis, and a consensus sequence for the amplified gene was generated using oligonucleotide primers.
  • the purified LI PCR product was directly subcloned into the vector pGEM-T to create plasmid pGW-A.
  • LI gene was generated from the pGW-A template using the same oligonucleotide primers as for the consensus sequence.
  • the sequence of the cloned E7 gene was shown to be identical to that of the consensus.
  • PCR products were purified from agarose gels by binding to silica matrix and ligated to pGEM-T vector DMA. The products of these ligation reactions were used to transform E. coli DH5a cells. Recombinant clones were isolated and further screened for the correct HPV-6 gene inserts using a method based on PCR.
  • HPV-6 The consensus sequence was compared to that of closely related HPV types including HPV-11. HPV-16 and HPV-18 as well as the published sequence of HPV-6b from the European Molecular Biology Laboratory (EMBL) DNA database to ensure that the genes amplified were from an HPV-6 type virus.
  • EMBL European Molecular Biology Laboratory
  • Comparisons were made with the help of Lasergene Navigator software (DNAStarlnc.) using the EditSeq, SeqMan, Megalign and Protean programs. Comparisons wre made at the DNA level and from the predicted amino acid sequences of the three genes.
  • suitable constructs for use in this invention can be made on the basis of DNA from wild-type clinical HPV isolates.
  • L2 and E7 were assembled to generate the fusion molecule in the following manner: Both the L2 and E7 genes were cloned by PCR amplification to introduce novel N- and C-terminal restriction enzyme sites, whilst maintaining the integrity of the protein sequence. These gene sequences were then ligated together into a cloning vector, using standard recombinant DNA techniques, to create a L2E7 fusion gene, so that the open reading frames of the two sequences were maintained.
  • the L2E7 fusion gene was constructed as follows.
  • HPV-6 L2 gene was initially generated as a l.lkb PCR fragment flanked by BamHI and Nco I sites. This PCR fragment was sub-cloned into the pGEM-T cloning vector. Clones possessing the required insert were digested with the two enzymes in order to liberate the L2 gene, which was then purified by separation on an agarose gel followed by extraction onto glass milk. Similarly the HPV-6 E7 gene was generated as a 300 bp Nco I - Sal I fragment, sub-cloned into pGEM-T. These two gene fragments were ligated together to produce a 1.4kb BamH I - Sal I DNA fragment which encoded an L2E7 fusion protein.
  • the resulting BamH I - Sal I DNA fragment was then ligated into a derivative of pET16b, a non-expressing cloning vector possessing kanamycin resistance.
  • the resulting construct was named pGW48.
  • the L2E7 gene fusion was subsequently transferred to an expressing pET vector in order to analyse the expression of the protein in E. coli.
  • the L2E7 fusion gene was then modified by PCR to generate BamH I and Not I termini capable of allowing the insertion of the gene cassette into an expression vector containing an in frame pelB leader sequence at the 5 * end and an in frame His Tag at the 3' end.
  • the PCR fragment was cloned through the pGEM-T vector, and finally transferred to a pET vector derived from pET22b. This final construct was named pGW53.
  • the fusion construct was transferred to a series of prokaryotic expression vectors known as pET vectors.
  • These well known vectors comprise strong bacteriophage T7 transcription and translation signals. Expression may then be induced by providing a source of T7 RNA polymerase in the host cell, under the control of the inducible lacUV ⁇ promoter. Addition of the inducer. IPTG. then results in conversion of the cell's resources into target gene expression. Potentially the desired product can then comprise more than 50* of the total cell protein.
  • the system is inducible. it can maintain the target gene sequence in a transcriptionally silent state prior to induction, allowing the expression of gene sequences which are potentially toxic to the host cell.
  • IPTG Addition of IPTG to a rapidly growing culture of cells transformed with the pET vector containing the target gene therefore leads to induction of the polymerase enzyme and concomitant expression of the cloned gene.
  • the protein product may either be secreted, or in the case of these HPV gene products directed into inclusion bodies.
  • the cloning step was performed by the introduction of a Bgl II restriction enzyme site at each end of the gene fragment by PCR mutagenesis, using the following oligonucleotide: NRW170 GTCGACAGATCTGGCACATAGTAGGGCCCGA SEQ ID NO 2 (Oligonucleotide for PCR cloning of HPV 6 L2E7 into pET vector. Introduction of BglII site into N-terminus of HPV 6 L2. No methionine codon is required for fusion into pET leader sequence (pelB).
  • the L2E7 fusion gene was then ligated into the following vectors: pETllb, pET12b, pET16b and pET22b, which differ in the nature of their N-terminal and C-terminal sequences.
  • the recombinant plasmids were then used to transform an appropriate host cell , HMS174, which contains the gene for T7 polymerase.
  • HMS174 an appropriate host cell
  • Other host cells that differ in their stringency of suppressing basal expression are available and have been successfully used in this method.
  • the bacteria were transferred to ice and the optical density was measured.
  • the bacterial cultures were harvested by centrifugation in a 15 ml Falcon tube for 10 minutes at 4,000 rpm. The supernatant was removed and the bacteria resuspended in TE at a final volume of 0.5 ml.
  • the gel was subjected to Western transfer, followed by probing with anti-L2 antisera generated by immunisation of sheep with E. coli- derived L2 fusion protein.
  • Western blotting allowed the visulisation of a large number of bands of molecular weight below that of the full-length species, presumably all of which are again generated by proteolytic degradation or premature termination of transcription or translation.
  • the initial SDS-PAGE analyses demonstrated the presence of a Coomassie-staining protein band with a size corresponding to that expected for the full-length L2E7 gene product.
  • there were a number of other bands visible which may correspond to either proteolytic fragments of L2E7 or to premature termination artifacts.
  • L2E7 fusion protein consisted of two major bands of 80 kD and 70 kD, while the LI product contained two major bands at 30 and 32 kD in addition to the presumed full length product of 60 kD.
  • DNA sequence analysis revealed that in both the sequences for LI and L2 there were stretches of poly-T consisting of between seven and nine T residues, which appeared to coincide with the positions of prematurely terminated fragments of both the LI and L2E7 molecules. It was suggested that these regions caused premature termination of either transcription or translation, most probably the former. This belief was supported by the observation of a poly-T tract in the terminator sequence for the T7 polymerase.
  • TTT encodes the amino acid phenylalanine (Phe), for which an alternative codon (TTC) exists. It was therefore decided to replace the TTT codon by mutation to generate the sequence TTC, thereby maintaining the reading frame and the natural protein sequence. This was chosen so as to leave unaffected, in this example, the properties of the product, by leaving unchanged the protein sequence of the i munotherapeutic reagent.
  • the mutation should increase yield of expressed protein product by minimising the level of artifacts due to premature ending of transcription or translation.
  • Mutation was performed by the PCR technique of gene overlap extension using oligonucleotides JCT61, JPC81 defined below, in which the natural DNA sequence is replaced by the mutant sequence in the relevant area.
  • the following oligonucleotides were employed in the mutagenesis:
  • HPV 6 L2 at DNA sequence positions 159 and 162 (MINI to TTCTTO).
  • JPC90 CGTA ⁇ CCCTTA ⁇ CTTCTCAGATGTGGCGGC SEQ ID No 5 Coding strand oligonucleotide primer for HPV 6 L2 incorporating in vitro mutagenesis of the sequence at position 1359 and 1362
  • the final gene product was then inserted in order to create a final expression vector designed as pGW53 and analysed by in vitro and in vivo expression.
  • E.coli HMS174 cells containing the pGW53 plasmid and derived as described herein are laid down and stored at -80°C.
  • an ampoule from the working cell bank is thawed and cultured in 2YT medium to an appropriate volume for fermenter inoculation.
  • Fermentation scale can range from 1.3L to 50L and further scale up may be envisaged.
  • Cells were cultured until cell density reaches a preset point (typically 0.3g per L). At this point the culture is induced with IPTG after which the cells are harvested some 2 hours later. Yields of 24-50 mg L2E7 per g dry wt cells have been obtained on occasions using standard fermentation conditions.
  • Cell disruption and protein purification are then carried out as indicated below and in Figure 3 of the accompanying drawings.
  • IB's intracellular inclusion bodies
  • E.coli cell lysate containing insoluble L2E7 in the form of inclusion bodies is centrifuged.
  • the sedimented pellet, containing inclusion bodies and cell debris was resuspended in a buffer containing Triton X-100 detergent.
  • tangential cross-flow filtration which is a per-se standard technique carried out in commercially-obtainable "Filtron" (TM) apparatus, a flow of liquid or suspension to be ultrafiltered or filtered is passed across an ultrafiltration or filtration membrane under a transmembrane pressure sufficient to drive filtrate through the membrane.
  • tangential cross-flow filtration is used to concentrate the inclusion body suspension against a O.l ⁇ m filter.
  • Inclusion bodies are concentrated in the retentate and contaminants are removed in the filtrate.
  • the concentrate is then diluted to reduce the Triton X-100 concentration, and concentrated again.
  • Urea and DTT dithiothreitol are then added to a final concentration of 8M, and lOmM respectively, which solubiuses the L2E7.
  • Denatured, reduced L2E7 protein then passes through the 0.16 ⁇ filter into further filtrate where it is collected.
  • the L2E7 in denatured, reduced, filtered form is then purified using ion exchange chromatography.
  • 8.0M urea solubiused L2E7 protein is first purified by anion exchange chromatography using conditions indicated in Figure 3.
  • l-2g of the product are purified on a 250-350mL column.
  • Urea-solubiUsed L2E7 is loaded onto the anion exchange resin, and weakly bound contaminants removed by elution with 4 column volumes of Urea DTT Tris buffer (pH 8.0) containing 50mM NaCl.
  • L2E7 protein is eluted from the column using a maximum of 5 column volumes of urea DTT Tris buffer (pH 8.0) containing 350mM salt. Flow rate throughout the step is about 5ml cm ' Vminute.
  • the anion exchange chromatography peak product is loaded onto a cation exchanger. Typically l-2g of product are purified on about 250ml of column material. Product is loaded onto the resin at 2.5ml min cm '1 which is then washed with 4 column volumes of 8.0M urea DTT phosphate (pH 6.2) containing 210mM sodium chloride followed by L2E7 peak elution with wash buffer containing 500mM sodium chloride into approximately 1.5 column volumes.
  • the cation exchanger peak product was loaded onto a size exclusion matrix (as indicated in Figure 3) using a running buffer of 25mM Tris pH 8.0 containing 75mM sodium chloride. Typically 100ml containing 200-400mg of L2E7 is loaded (at 0.2ml cm "2 /min) onto 6.5L of matrix with a bed height of 100cm.
  • the peak corresponding to the major product and minor
  • N terminal clipped fragments was peak cut at an approximate elution volume of 0.46 column volumes.
  • the size exclusion chromatography peak at this stage of the process is dilute, at an approximate concentration of 0.25-0.5mg ml '1 .
  • the product (1-2L) is concentrated by loading onto a small volume of anion exchange matrix ( ⁇ 75ml) at a flow rate of 0.5ml cm 'z /min.
  • the product is eluted using urea DTT phosphate buffer pH 8.0 containing 1.0M sodium chloride.
  • the peak volume is 1-2 column volumes.
  • the concentrated Q anion cartridge peak was buffer exchanged into a final formulation buffer at 48.9mM Tris pH 8.0 containing 5mM DTT.
  • the column matrix is Sepharose medium G25 with a volume of -2.5 litres.
  • a 'slug' of buffer containing 8M urea equal to the product volume is preloaded onto the column.
  • the product is then loaded at a -100-150 mis load.
  • the formulated buffer exchanged product peak is typically eluted at 0.5 column volumes using a flow rate of 0.06ml cm ' Vmin.
  • the final product bulk is then -80°C stored.
  • a solution or dispersion of the product L2E7 protein obtainable in this way is in an aggregated (reaggregated) form, which can nevertheless pass through a sterilising filter, e.g. a filter of gauge in the range 0.16-0.22 micron, e.g. 0.2 micron.
  • a sterilising filter e.g. a filter of gauge in the range 0.16-0.22 micron, e.g. 0.2 micron.
  • the genes for the L2E7 fusion construct and for LI have been cloned into a generally available S. cerevisiae autonomously replicating expression vector.
  • This vector based on elements of the 2 ⁇ plasmid. allows expression of heterologous in-frames genes driven by the GAL7 promoter.
  • the vector also contains the LEU-2d marker, for selection of increased copy numbers in yeast cells, and the kanamycin resistance gene enabling selection in Escherichia coli.
  • the Saccharomyces host strain used for expression was S150-2B (genotype: a. leu2-3. 112. ⁇ his3. trpl-289. ura3-52).
  • Yeast were transformed with the HPV-6L2-E7 construct and grown up in medium containing 2* glucose as the sole carbon source, in order to repress transcription from the GAL7 promoter. Gene expression was induced in the presence of 2* galactose in the medium, as the sole carbon source.
  • Cell extracts were produced by disruption of the cell membranes in the presence of glass beads.
  • the extraction buffer was Tris-based and contained a broad range protease inhibitors; PMSF, pepstatin. leupeptin. antipain and chymostatin.
  • Cell extracts were processed by SDS PAGE and the resolved proteins were Western blotted using polyclonal antisera raised in sheep against HPV-6 L2 and HPV-6 E7.
  • An L2E7 fusion molecule (see Example 3 above) can be created as a BamH I - Not I DNA fragment, and cloned into a suitable expression vector such as a Pichia expression vector pPIC3K (obtained under license from Phillips Petroleum).
  • the gene can be placed under the control of the Alcohol Oxidase promoter. AOXI. in order to allow high level expression of the fusion protein.
  • the DNA can be transfected into yeast cells by spheroplast fusion.
  • Transforants can be selected by their ability to grow in minimal media in the absence of histidine, unlike untransfected cells which retain the requirement for histidine in the growth medium.
  • a second round of screening on the basis of slow growth on a methanol substrate can be performed to select for those clones containing an L2E7 gene integrated at the correct locus.
  • the two constructs were cloned by PCR amplification, which introduced terminal Bgl II sites, into the pGEM-T vector.
  • the L2E7 genes were then isolated as Bgl II - Bgl II fragments and subcloned into the BamHI cloning site of the transfer vector pBacPAKl (Clontech).
  • the orientation of the inserts were then determined by PCR analysis, and DNA was prepared from clones containing the correct orientation.
  • DNA from the pBacPAKl transfer vector containing either L2E7 construct was transfected, using the standard lipofectin mediated procedure, into Spodoptera frugiperda (type Sf9) cells along with Bsu36 1 cut PBacPAKl viral DNA (Clontech). In vivo homologous recombination between the plasmid and viral DNA then occurs to rescue the viral DNA, and in the process the target gene is transferred to the viral genome.
  • the progeny viruses generated in the co-transfection supernatant were then amplified by infecting fresh cells.
  • a fraction of the infected cells were harvested and genomic DNA was prepared. PCR amplification using the above primers indicated that recombinant virus was present in the cells.
  • the passage one virus stock was then used to further infect cells at a high multiplicity of infection to characterise gene expression by determining the time course of protein production: Confluent Sf9 cells in 6 well dishes were infected at a high multiplicity of infection, cells and supernatant were harvested 24 hrs.48 hrs and 72 hrs post infection. The results of the experiment were observed by SDS-PAGE analysis and Western blotting in order to detect synthesis of the protein.
  • Recombinant protein was not observed on a Coomassie stained SDS/PAGE gel but was detected at low levels by Western blotting. As expected the protein was not secreted due to the absence of a leader sequence.
  • the amplified genes were sequenced in full and subcloned into plasmid vectors. The gene sequences have been used to contruct gene fusions for expression of HP -6 proteins to high levels in prokaryotic and eukaryotic systems.
  • L2E7 The immunogenicity of an aggregate of L2E7 has been examined in mice. It was found that when an aggregate of L2E7 adsorbed onto aluminium hydroxide ('alum') was injected into B6CBA mice L2E7 specific immunity was elicited. This L2E7 specific immunity included serum antibodies, of immunoglobulin G (IgG) class and immunoglobulin Gl subclass (IgGl). L2E7 specific delayed type hypersensitivity responses and lymphoproliferative responses in vitro were also found.
  • IgG immunoglobulin G
  • IgGl immunoglobulin Gl subclass
  • L2E7 adsorbed onto alum was examined in B6CBA mice. Mice were given two subcutaneous injections of 180 ⁇ g L2E7/Alum 14 days apart.
  • Serum anti-L2E7 antibody levels were determined in an L2E7 specific enzyme linked immunosorbent assay. Serum anti-L2E7 responses peaked 14 days after the 2nd injection of L2E7 (mid point titre 4.572 loglO) and persisted to 56 days (mid point titre 4.127 loglO).
  • DTH delayed type hypersensitivity responses
  • lymph node cells axillary lymph node cells
  • L2E7 / alum product as above.
  • a single lymph node cell suspension was made and 2xlO A 6 viable lymphocytes/ml were plated out in medium (Iscove's modified Dulbecco's medium) supplemented with 1* normal mouse serum, glutamine, beta- mercaptoethanol and antibiotics.
  • L2E7 was titrated into the cultures (from 91 micro-g/ml) and cell proliferation was assessed by incorporation of tritiated thymidine for the final 24 hours of the 72 hour culture. Lymph node cells from mice were immunized with L2E7/Alum proliferated in vitro in response to L2E7 (42000 cp . stimulation index 50).
  • Cells from all of 36 vaccinated volunteers showed a L2E7-specifie in-vitro lymphoproliferative response (CD4+ T cells) indicative of immune response to the product.
  • the volunteers had been given the product by intramuscular injection in doses of 3. 30 or 300 ⁇ g, an initial dose at day 0 and repeated doses on day 7 and day 28 (accelerated schedule). (An alternative, slower, schedule for vaccination on days 0. 28 and 56 was also tried, and found less preferable.) Lymphoproliferative responses were seen from day 7 at dose levels including the lowest dose, 3 ⁇ g.
  • L2E7 specific antibody response was also shown in 29 of 32 assessable samples from the volunteers (the three non-responders in the antibody test had been given the lowest dose). Increased in-vitro production of IL-5, consistent with the antibody production, was also seen. The two higher doses elicited T-cell proliferation sooner than the lowest dose. The highest dose, 300 ⁇ g, stimulated more IFN-gamma production than the lower doses. The observations made, of rapid T-cell proliferation and associated production of IFN-gamma, are appropriately consistent with the intended use of the product as a therapeutic vaccine for genital warts.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des polypeptides hybrides et des agrégats de polypeptides comprenant des antigènes dérivés du papillomavirus, sur des compositions desdits polypeptides et sur l'utilisation desdites compositions avec, par exemple, des adjuvants à des fins immunogènes ou de vaccination pour induire, par exemple, des réponses immunitaires spécifiques au PVH. On peut purifier les polypeptides pour obtenir des agrégats qui, sous forme de solution ou de dispersion, peuvent être passés à travers un filtre stérile et donner des agrégats amorphes. Un exemple d'un tel polypeptide est une protéine hybride de la famille des protéines L2 et E7 du papillomavirus humain.
PCT/GB1996/001816 1996-07-29 1996-07-29 Polypeptides utiles comme agents d'immunotherapie et procedes de preparation de polypeptides WO1998004706A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CZ99288A CZ28899A3 (cs) 1996-07-29 1996-07-29 Polypeptidy použitelné jako imunoterapeutická činidla a způsoby přípravy polypeptidů
PCT/GB1996/001816 WO1998004706A1 (fr) 1996-07-29 1996-07-29 Polypeptides utiles comme agents d'immunotherapie et procedes de preparation de polypeptides
HU9904137A HUP9904137A3 (en) 1996-07-29 1996-07-29 Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
NZ333799A NZ333799A (en) 1996-07-29 1996-07-29 Composition comprising an antigenic determinant of a papillomavirus protein in amorphous aggregated form
BR9612675A BR9612675A (pt) 1996-07-29 1996-07-29 Polipeptídeo ou composicão de polipeptídeo composicão imunogenica adequada para admistracão por injecao e uso de polipeptideo ou de composicão imunogenica
IL12826996A IL128269A0 (en) 1996-07-29 1996-07-29 Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
NO990398A NO990398L (no) 1996-07-29 1999-01-28 Polypeptider nyttige som immunoterapeutiske midler og metoder for polypeptidfremstilling
FI990157A FI990157A (fi) 1996-07-29 1999-01-28 Immunoterapeuttisina aineina käytt¦kelpoisia polypeptidejä sekä polypeptidivalmistuksen menetelmiä

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1996/001816 WO1998004706A1 (fr) 1996-07-29 1996-07-29 Polypeptides utiles comme agents d'immunotherapie et procedes de preparation de polypeptides

Publications (1)

Publication Number Publication Date
WO1998004706A1 true WO1998004706A1 (fr) 1998-02-05

Family

ID=10787784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001816 WO1998004706A1 (fr) 1996-07-29 1996-07-29 Polypeptides utiles comme agents d'immunotherapie et procedes de preparation de polypeptides

Country Status (5)

Country Link
CZ (1) CZ28899A3 (fr)
FI (1) FI990157A (fr)
HU (1) HUP9904137A3 (fr)
IL (1) IL128269A0 (fr)
WO (1) WO1998004706A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000242A2 (fr) * 2000-06-26 2002-01-03 Stressgen Biotechnologies Corporation Traitement des infections par le papillomavirus
WO2003068940A2 (fr) * 2002-02-14 2003-08-21 Curagen Corporation Complexes et procedes d'utilisation correspondants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005248A1 (fr) * 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Expression de proteines virales du papillome humain et utilisation dans des compositions immunogeniques
WO1992016636A1 (fr) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Vecteurs viraux recombinants codant pour des proteines du papillomavirus humain
WO1996011274A1 (fr) * 1994-10-06 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules de type papillomavirus chimeriques
WO1996026277A1 (fr) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005248A1 (fr) * 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Expression de proteines virales du papillome humain et utilisation dans des compositions immunogeniques
WO1992016636A1 (fr) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Vecteurs viraux recombinants codant pour des proteines du papillomavirus humain
WO1996011274A1 (fr) * 1994-10-06 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules de type papillomavirus chimeriques
WO1996026277A1 (fr) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CASON J ET AL: "DETECTION OF PROTEIN AGGREGATES, BUT NOT VIRUS-LIKE PARTICLES, WHEN THE MAJOR (L1) COAT PROTEIN OF A WILD-TYPE HUMAN PAPILLOMAVIRUS TYPE 16 (HPV-16) IS EXPRESSED IN INSECT CELLS", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 22, no. 3, August 1994 (1994-08-01), pages 335S, XP000603038 *
KELSALL S R ET AL: "EXPRESSION OF THE MAJOR CAPSID PROTEIN OF HUMAN PAPILLOMARVIRUS TYPE 16 IN ESCHERICHIA COLI", JOURNAL OF VIROLOGICAL METHODS, vol. 53, no. 1, 1995, pages 75 - 90, XP000602999 *
KIM, K. J. ET AL: "Some factors determining protein aggregation during ultrafiltration", BIOTECHNOL. BIOENG. (1993), 42(2), 260-5 CODEN: BIBIAU;ISSN: 0006-3592, XP000647833 *
KOECHEL H G ET AL: "OCCURRENCE OF ANTIBODIES TO L1, L2, E4 AND E7 GENE PRODUCTS OF HUMAN PAPILLOMAVIRUS TYPES 6B, 16 AND 18 AMONG CERVICAL CANCER PATIENTS AND CONTROLS", INT.J.CANCER, vol. 48, no. 5, 9 July 1991 (1991-07-09), pages 682 - 688, XP000572700 *
MANDELSON M T ET AL: "THE ASSOCIATION OF HUMAN PAPILLOMAVIRUS ANTIBODIES WITH CERVICAL CANCER RISK", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, vol. 1, no. 4, 1 May 1992 (1992-05-01), pages 281 - 286, XP000572696 *
ROSE R C ET AL: "EXPRESSION OF HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN IN INSECT CELLS: IN VIVO AND IN VITRO ASSEMBLY OF VIRUSLIKE PARTICLES", JOURNAL OF VIROLOGY, vol. 67, no. 4, 1 April 1993 (1993-04-01), pages 1936 - 1944, XP000565840 *
SUTTNAR J ET AL: "PROCEDURE FOR REFOLDING AND PURIFICATION OF RECOMBINANT PROTEINS FROM ESCHERICHIA COLI INCLUSION BODIES USING A STRONG ANION EXCHANGER", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL APPLICATIONS, vol. 656, no. 1, 3 June 1994 (1994-06-03), pages 123 - 126, XP000601830 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000242A2 (fr) * 2000-06-26 2002-01-03 Stressgen Biotechnologies Corporation Traitement des infections par le papillomavirus
WO2002000242A3 (fr) * 2000-06-26 2002-10-03 Stressgen Biotechnologies Corp Traitement des infections par le papillomavirus
US6797491B2 (en) * 2000-06-26 2004-09-28 Stressgen Biotechnologies Corporation Human papilloma virus treatment
US7211411B2 (en) 2000-06-26 2007-05-01 Nventa Biopharmaceuticals Corporation Human papilloma virus treatment
CN100441223C (zh) * 2000-06-26 2008-12-10 尼文塔生物制药公司 人乳头状瘤病毒治疗
US7754449B2 (en) 2000-06-26 2010-07-13 Nventa Biopharmaceuticals Corporation Human papilloma virus treatment
WO2003068940A2 (fr) * 2002-02-14 2003-08-21 Curagen Corporation Complexes et procedes d'utilisation correspondants
WO2003068940A3 (fr) * 2002-02-14 2003-11-27 Curagen Corp Complexes et procedes d'utilisation correspondants

Also Published As

Publication number Publication date
FI990157A0 (fi) 1999-01-28
CZ28899A3 (cs) 1999-07-14
HUP9904137A3 (en) 2001-06-28
FI990157A (fi) 1999-01-28
IL128269A0 (en) 1999-11-30
HUP9904137A2 (hu) 2000-04-28

Similar Documents

Publication Publication Date Title
US6123948A (en) Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
JP5296665B2 (ja) ヒトパピローマウイルスカプソメアワクチン製剤の製造方法
US6365160B1 (en) Papillomavirus polyprotein constructs
KR101170654B1 (ko) 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현
DK2910566T3 (en) Truncated L1 protein of human papillomavirus 11
KR20120098580A (ko) 인간 파필로마바이러스（ｈｐｖ） 단백질 작제물 및 ｈｐｖ 질환을 예방하기 위한 이의 용도
CN106831958B (zh) 一种人乳头瘤病毒11型l1蛋白的突变体
US7279306B2 (en) Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof
US8039001B2 (en) Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
CN106831961A (zh) 一种人乳头瘤病毒58型l1蛋白的突变体
WO1998004706A1 (fr) Polypeptides utiles comme agents d'immunotherapie et procedes de preparation de polypeptides
AU4454499A (en) Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
AU3560202A (en) Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
KR20210018312A (ko) 인유두종 바이러스 18 엘1 단백질의 돌연변이체
MXPA99000963A (en) Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
CN1229437A (zh) 用作为免疫治疗剂的多肽和制备多肽的方法
KR20000029687A (ko) 면역치료제로서유용한폴리펩티드및폴리펩티드의제조방법
MXPA00003358A (en) Papilloma virus capsomere vaccine formulations and methods of use
MXPA06005306A (en) Optimized expression of hpv 58 l1 in yeast

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96180428.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AZ BB BG BR BY CN CU CZ EE FI GE HU IL IS KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 333799

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/000963

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV1999-288

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 990157

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1019997000766

Country of ref document: KR

Ref document number: 1999/00160

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: PV1999-288

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997000766

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019997000766

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-288

Country of ref document: CZ